Revvity Inc. stock gains on Goldman Sachs price target hike

Revvity Inc. stock (ISIN US76155R1086) ended trading on the New York Stock Exchange at USD 143.45 on September 21, 2026, giving the diagnostics and research company a market capitalization of about USD 16.0 billion and extending a sharp rally over recent months.

Goldman Sachs lifts target as rally continues

According to Futunn on September 21, 2026, Goldman Sachs raised its price target on Revvity from USD 100 to USD 140 and maintained its Neutral rating, signaling that the bank sees fundamental progress but limited upside after the recent share price surge.

As MarketScreener reported on September 21, 2026, Revvity shares recently traded around USD 142.70 in real-time data, with a five-day performance of roughly flat but a year-to-date gain of 10.85 percent and an increase of about 47.2 percent over the past year, underlining how far the stock has already run.

Morningstar highlighted that Revvity gained 15.40 percent over the past week, 43.54 percent over the past three months and 63.91 percent over the past year, leaving the shares about 18 percent above Morningstar's fair value estimate of USD 122 and earning a 2-star rating that signals overvaluation at current levels, according to Morningstar on September 21, 2026.

Strong earnings underpin the move

Life-sciences company Revvity continued to rally on the heels of strong earnings published last month, with the stock ranking among the biggest gainers in the S&P 500 over the past week, according to TradeStation on September 21, 2026.

Segment data compiled by TradingView show that in the most recently reported fiscal year, Revvity generated USD 2.86 billion in revenue, of which USD 1.43 billion came from the Life Sciences segment compared with USD 1.25 billion for that segment in the prior year, marking Life Sciences growth of about 14.4 percent year-on-year.

The remaining revenue came from other segments such as Diagnostics and research tools, illustrating that Revvity has a diversified revenue base across laboratories, pharma and healthcare customers. For investors, the double-digit expansion in Life Sciences forms a key part of the growth story that has helped drive the stock's recent re-rating.

Analyst consensus and valuation signals

Analyst consensus compiled by MarketScreener on September 21, 2026 indicates that 19 analysts cover Revvity with an average recommendation of Accumulate, a last closing price of USD 143.45 and an average price target of USD 128.47, implying that the stock trades more than 10 percent above the mean target.

Recent rating changes reflect this tension between strong operational performance and a richer valuation. MarketScreener notes that RBC Capital Markets moved Revvity from Buy to Neutral on September 1, 2026, UBS shifted its view to Neutral on September 9, 2026, while KeyBanc Capital Markets and Baird have maintained Buy recommendations earlier in the month, as reported by MarketScreener.

Morningstar's classification of Revvity as a small-core stock without an economic moat and trading at an 18 percent premium to its USD 122 fair value estimate, combined with Goldman Sachs' Neutral rating and USD 140 target, suggests that much of the near-term optimism is already priced into the shares, even though the underlying business continues to grow.

Stock performance and trading data

Per New York Stock Exchange data cited by Yahoo Finance on September 20, 2026, Revvity closed at USD 143.45, corresponding to a market capitalization of about USD 16.0 billion in the Diagnostics and Research industry. Over the week of mid-September, Dow Jones data reported that Revvity stock climbed 9.1 percent on September 15, 2026 and 4.0 percent on September 16, 2026, significantly outperforming sector peers during those sessions, according to Dow Jones.

MarketScreener's overview on September 21, 2026 shows Revvity trading near USD 142.67 in estimated real-time data, with a five-day variation of around minus 0.54 percent, year-to-date performance of 10.85 percent, and a 52-week move of about 47.22 percent to the upside, underscoring the stock's strong longer-term trajectory even after short-term swings, according to MarketScreener.

Fact box: Revvity Inc. stock at a glance

More news and analyses on Revvity Inc. stock